Thermal Ablation of Cervical Metastases From Thyroid Carcinoma
NCT: NCT04522570 · COMPLETED
Brief Summary
This study will evaluate the clinical response and safety of ultrasound guided percutaneous thermal ablation of lymph node metastases from thyroid carcinoma as an alternative to surgical treatment. The ablation of cervical lymph node metastases from differentiated thyroid carcinoma or medullary thyroid carcinoma will be directed to lesions larger than 0.8 cm, using ultrasound-guided radiofrequency ablation (RFA), laser ablation (LA) or cryoablation (Cryo) techniques, randomly assigned. Clinical and ultrasound monitoring will be carried out during 24 months, with examinations before the ablation procedure, immediately after including contrast-enhanced ultrasound (CEUS) when applicable, and B-mode, color Doppler and Shear-Wave elastography ultrasound follow up with 6, 12, and 24 months.
Frequently Asked Questions
What is Thermal Ablation of Cervical Metastases From Thyroid Carcinoma?
Thermal Ablation of Cervical Metastases From Thyroid Carcinoma is a clinical trial registered under NCT04522570. Current status: COMPLETED.
What is the status of NCT04522570?
The current status of NCT04522570 (Thermal Ablation of Cervical Metastases From Thyroid Carcinoma) is: COMPLETED.
When did Thermal Ablation of Cervical Metastases From Thyroid Carcinoma start?
Thermal Ablation of Cervical Metastases From Thyroid Carcinoma started on 2020-12-22.
Related Devices
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.